Cookies on the
LGC website
We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we’ll assume that you are happy to receive all cookies on the LGC website. However, if you would like to, you can change your cookie settings at anytime.
Question markFind out more

LGC acquires Prime Synthesis, Inc., and strengthens its supply of oligo synthesis materials

18 Nov 2016
Tags:  Genomics
LGC, the international life sciences and measurement company, has announced that it has acquired Prime Synthesis, Inc. (PSI), the leading producer of Controlled Pore Glass (CPG) supports for oligonucleotide synthesis. Complementing LGC’s existing genomics offering, PSI’s products are supplied to the pharma and biopharma, academic research, CMOs, medical diagnostics and biochemical reagents markets.

The combination of the PSI business with the LGC Biosearch  CPG production facility in Steinach, Germany  provides increased supply chain resiliency for our clients based on the manufacturing footprint in  both the US and Europe.  It also provides a platform for scale up of CPG production, which is important for our Pharmaceutical customers conducting late stage clinical trials with oligo therapeutic candidates.

Daren Dick, Vice President and General Manager, LGC Biosearch, Genomics division, said, “We are delighted to be integrating PSI to our genomics division. The acquisition will enable us to provide customers across the world with an extended products line, and strengthen our supply of oligo synthesis materials. “

Marc Rothstein, President, Prime Synthesis, said, “We are looking forward to joining forces with LGC and integrating our teams and expertise. Since its creation in the late 1980s, PSI has become a leading provider of CPG, a critical raw component in the genomics market. The integration with LGC will enable us to provide customers with a combined capability and provides increased supply robustness.”